Subscribe to our newsletter to receive the latest product updates and special offers

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

New on Charts:

We've added Splits, Dividends, Earnings, and Earnings Estimates! Click on individual events to unveil more details.

If you prefer a cleaner view, easily disable them in Settings.

KNSA | Kiniksa Pharmaceuticals Ltd

IndexRUT P/E4.76 EPS (ttm)3.27 Insider Own52.11% Shs Outstand34.75M Perf Week-6.68%
Market Cap1.09B Forward P/E- EPS next Y-0.36 Insider Trans-0.08% Shs Float33.60M Perf Month-12.36%
Income231.26M PEG- EPS next Q-0.17 Inst Own49.34% Short Float / Ratio11.37% / 8.00 Perf Quarter12.38%
Sales280.84M P/S3.89 EPS this Y- Inst Trans-0.13% Short Interest3.82M Perf Half Y41.89%
Book/sh5.88 P/B2.65 EPS next Y-55.81% ROA66.56% Target Price21.20 Perf Year21.22%
Cash/sh2.64 P/C5.90 EPS next 5Y- ROE81.84% 52W Range10.29 - 20.65 Perf YTD3.91%
Dividend- P/FCF23.85 EPS past 5Y- ROI54.68% 52W High-24.62% Beta-0.21
Dividend %- Quick Ratio4.68 Sales past 5Y94.25% Gross Margin76.13% 52W Low51.26% ATR0.74
Employees220 Current Ratio5.18 Sales Q/Q164.99% Oper. Margin13.57% RSI (14)36.54 Volatility4.45% 3.95%
OptionableYes Debt/Eq0.03 EPS Q/Q- Profit Margin82.35% Rel Volume0.52 Prev Close16.90
ShortableYes LT Debt/Eq0.03 EarningsJul 25 BMO Payout0.00% Avg Volume477.22K Price15.56
Recom1.00 SMA20-9.07% SMA50-11.05% SMA2007.01% Volume228,671 Change-7.90%
Date Action Analyst Rating Change Price Target Change
Jun-29-20Reiterated BofA Securities Buy $25 → $40
Apr-01-20Initiated BofA/Merrill Buy $25
Mar-11-19Initiated Barclays Overweight $26
Dec-12-18Reiterated Wedbush Outperform $31 → $33
Jun-19-18Initiated JMP Securities Mkt Outperform $33
Sep-29-23 12:43PM
Aug-27-23 08:40AM
Aug-22-23 08:14AM
Aug-18-23 09:04PM
Aug-10-23 10:33PM
06:14AM Loading…
Aug-07-23 06:14AM
Jul-25-23 10:05PM
01:06PM
08:45AM
07:30AM
Jul-24-23 08:31AM
Jul-18-23 04:01PM
Jul-17-23 08:00AM
Jul-04-23 08:24PM
Jun-06-23 04:01PM
06:14AM Loading…
May-03-23 06:14AM
May-02-23 08:45AM
07:30AM
May-01-23 04:01PM
Apr-09-23 09:21AM
Apr-05-23 01:40PM
Mar-31-23 09:35AM
Mar-30-23 02:20PM
Mar-29-23 10:13AM
Mar-27-23 12:04PM
Mar-23-23 02:25PM
Mar-03-23 06:57PM
Feb-28-23 11:25AM
08:00AM
Feb-27-23 04:01PM
11:47AM Loading…
11:47AM
Feb-23-23 10:50AM
Jan-25-23 02:52AM
Jan-21-23 04:51PM
Jan-09-23 08:00AM
Jan-03-23 04:01PM
Nov-30-22 04:01PM
Nov-23-22 04:01PM
Nov-10-22 09:40AM
Nov-07-22 09:55AM
08:50AM
Nov-01-22 09:15AM
08:00AM
Oct-31-22 04:01PM
Oct-24-22 09:40AM
Oct-05-22 08:50AM
Sep-21-22 12:00PM
Sep-20-22 10:30AM
Sep-12-22 08:30AM
Aug-22-22 09:55AM
Aug-05-22 09:55AM
Aug-04-22 09:09AM
Aug-03-22 04:01PM
09:40AM
08:45AM
08:30AM
07:30AM
07:29AM
Aug-02-22 04:01PM
Jul-22-22 12:00PM
Jun-22-22 09:14AM
Jun-19-22 09:49AM
May-05-22 06:52AM
May-03-22 09:15AM
May-02-22 04:01PM
Apr-13-22 09:08AM
Feb-22-22 09:15AM
08:00AM
07:59AM
Feb-18-22 04:01PM
Jan-10-22 08:00AM
Jan-03-22 04:01PM
07:09AM
Dec-31-21 10:00AM
Dec-29-21 09:37AM
Dec-28-21 07:40AM
06:59AM
05:26AM
Dec-01-21 10:00AM
Nov-23-21 04:01PM
Nov-19-21 10:18AM
Nov-04-21 11:38AM
Nov-03-21 10:33AM
Nov-01-21 09:15AM
08:00AM
Oct-29-21 04:01PM
Sep-21-21 04:01PM
Aug-16-21 08:00AM
Aug-03-21 09:15AM
08:00AM
Aug-02-21 04:01PM
Jul-26-21 03:00PM
Jul-20-21 04:01PM
Jun-08-21 04:01PM
07:30AM
Jun-01-21 04:01PM
May-10-21 05:49AM
May-04-21 08:00AM
07:59AM
Apr-12-21 07:30AM
Kiniksa Pharmaceuticals Ltd. is a biopharmaceutical company, which engages in discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical need. Its products include Rilonacept, Mavrilimumab, Vixarelimab, and KPL-404. The company was founded by Sanj K. Patel, Stephen Frank Mahoney, Krisha S. Mahoney, Thomas W. Beetham, Christopher Heberlig, Carsten Boess, Rasmus Holm-Jorgensen, Gregory Alex Grabowksi, Aaron Isadore Young, Eben P. Tessari, Jennifer Lynne Mason and Mickenzie Elizabeth Gallagher in July 2015 and is headquartered in Lexington, MA.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Paolini John F.CHIEF MEDICAL OFFICERSep 05Option Exercise1.8640074445,292Sep 06 07:03 PM
Paolini John F.CHIEF MEDICAL OFFICERSep 05Sale17.534007,01244,892Sep 06 07:03 PM
Paolini John F.CHIEF MEDICAL OFFICERJul 25Option Exercise1.8629,00053,94070,910Jul 27 04:30 PM
Paolini John F.CHIEF MEDICAL OFFICERJul 25Sale19.1429,000555,16041,910Jul 27 04:30 PM
Quart Barry DDirectorNov 29Option Exercise1.5921,95934,91521,959Dec 01 04:16 PM
Quart Barry DDirectorNov 29Sale16.1521,959354,6380Dec 01 04:16 PM
Paolini John F.CHIEF MEDICAL OFFICERNov 07Option Exercise1.8628,35752,74464,692Nov 09 04:16 PM
Paolini John F.CHIEF MEDICAL OFFICERNov 07Sale15.1828,357430,45936,335Nov 09 04:16 PM